Last reviewed · How we verify

Array Biopharma, now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief

Array Biopharma, now a wholly owned subsidiary of Pfizer pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Atriva Therapeutics GmbH · 1 shared drug class
  3. IDEAYA Biosciences · 1 shared drug class
  4. Pierre Fabre Medicament · 1 shared drug class
  5. West China Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Array Biopharma, now a wholly owned subsidiary of Pfizer:

Cite this brief

Drug Landscape (2026). Array Biopharma, now a wholly owned subsidiary of Pfizer — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer. Accessed 2026-05-17.

Related